About Glycominds, LLC

 

Glycominds is a leading groundbreaker in microbiome biomarker research, offering the only validated serum biomarker tests on the market for Inflammatory Bowel Disease. Our analytes produce results from a strong and proprietary technology platform, providing answers to physicians and allowing many patients to benefit from personalized control over their diagnosis and/or progression of their disease.

 

Glycominds, an innovative diagnostics company, discovers, develops and commercializes gastrointestinal disease diagnostic reagents (USA) and kits (Ex-USA). Our proprietary biomarkers allow physicians to help identify patients who have Inflammatory Bowel Diseases (mainly Crohn’s Disease and Ulcerative Colitis) to achieve early, non-invasive, accurate and cost-effective diagnosis, predict Crohn’s Disease patients at a higher risk for more complicated disease, as well as monitoring Anti-TNF therapy response.

​

https://www.crohnscolitisfoundation.org/research/grants-fellowships/entrepreneurial-investing/portfolio